1 / 1

SPRINT-1 Study Design

PART 1. PART 2 a. SPRINT-1 Study Design. Week 28. Week 4. Week 48. Peg-IFN  2b 1.5 μ g/kg + RBV 800-1400 mg for 48 wks . 24 wks Follow-up. N=104. Control. 44 wks Follow-up. Peg-IFN  2b + RBV 800-1400 mg. Peg-IFN  2b 1.5 μ g/kg + RBV 800-1400mg +

herbst
Download Presentation

SPRINT-1 Study Design

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PART 1 PART 2a SPRINT-1 Study Design Week 28 Week 4 Week 48 Peg-IFN2b 1.5 μg/kg + RBV 800-1400 mg for 48 wks 24 wks Follow-up N=104 Control 44 wks Follow-up Peg-IFN2b + RBV 800-1400 mg Peg-IFN2b 1.5 μg/kg + RBV 800-1400mg + Boceprevir 800 mg TID for 28 wks N=103 Lead-in Strategy Peg-IFN2b + RBV 800-1400 mg Peg-IFN2b 1.5 μg/kg + RBV 800-1400 mg + Boceprevir 800 mg TID for 44 wks 24 wks Follow-up N=103 Peg-IFN2b 1.5 μg/kg + RBV 800-1400 mg + Boceprevir 800 mg TID for 28 wks 44 wks Follow-up N=107 No Lead-in Strategy Peg-IFN2b 1.5 μg/kg + RBV 800-1400 mg + Boceprevir 800 mg TID for 48 wks 24 wks Follow-up N=103 Peg-IFN2b 1.5 μg/kg + RBV 800-1400 mg + Boceprevir 800 mg TID for 48 wks 24 wks Follow-up N=16 Low Dose RBV Strategy Peg-IFN2b 1.5 μg/kg + RBV 400-1000 mg + Boceprevir 800 mg TID for 48 wks 24 wks Follow-up N=59 aPart two consisted of 75 patients at 10 US sites, 1:4 randomization.

More Related